Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).

被引：0
|
作者：
Desai, Kunal
Rybicki, Lisa A.
Nizam, Amanda
Wood, Laura S.
Allman, Kimberly D.
Martin, Allison
Calabrese, Cassandra
Gilligan, Timothy D.
Gupta, Shilpa
Ornstein, Moshe Chaim
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17094
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study
    Nukaya, Takuhisa
    Takahara, Kiyoshi
    Yoshizawa, Atsuhiko
    Saruta, Masanobu
    Yano, Yusuke
    Ohno, Takaya
    Uchimoto, Taizo
    Fukuokaya, Wataru
    Adachi, Takahiro
    Yamazaki, Shogo
    Tokushige, Satoshi
    Nishimura, Kazuki
    Tsujino, Takuya
    Nakamori, Keita
    Yamamoto, Shutaro
    Iwatani, Kosuke
    Urabe, Fumihiko
    Mori, Keiichiro
    Yanagisawa, Takafumi
    Tsuduki, Shunsuke
    Hirasawa, Yosuke
    Hashimoto, Takeshi
    Komura, Kazumasa
    Inamoto, Teruo
    Miki, Jun
    Kimura, Takahiro
    Ohno, Yoshio
    Azuma, Haruhito
    Shiroki, Ryoichi
    CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : 76 - 83
  • [2] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [3] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [4] The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE
    Kizawa, R.
    Kuno, M.
    Washino, S.
    Shirotake, S.
    Izumi, K.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Hyodo, Y.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    Miura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1488
  • [5] IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Muto, Yumina
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2022, 207 (05): : E175 - E175
  • [6] ASSOCIATION OF IMMUNE-RELATED ADVERSE EVENTS WITH PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Homma, Chie
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E71 - E71
  • [7] Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Ikeda, Takashi
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Takagi, Toshio
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    TARGETED ONCOLOGY, 2021, 16 (04) : 493 - 502
  • [8] Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Takashi Ikeda
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Toshio Takagi
    Hideki Ishida
    Tsunenori Kondo
    Kazunari Tanabe
    Targeted Oncology, 2021, 16 : 493 - 502
  • [9] Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
    Stuhler, Viktoria
    Herrmann, Lisa
    Rausch, Steffen
    Stenzl, Arnulf
    Bedke, Jens
    CANCERS, 2022, 14 (12)
  • [10] Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Homma, Chie
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (06) : 355.e21 - 355.e29
12345